Shanhe Pharmaceutical Auxiliary: Shareholder Fosun Pharma reduces holdings by approximately 2,325,700 shares

2026-02-26 03:32:07

Abstract generation in progress

Radar Finance | Feng Xiuyu Written | Li Yihui

On February 24, Anhui Shanhe Pharmaceutical Excipients Co., Ltd. (stock abbreviation: Shanhe Pharmaceutical Excipients) announced that the shareholding reduction plan by the shareholder holding more than 5%, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. (hereinafter referred to as “Fosun Pharma”), has been completed. Between November 24, 2025, and January 15, 2026, Fosun Pharma reduced its holdings by 2,325,700 shares through centralized bidding transactions, representing 1.00% of the total shares, with an average selling price of 16.42 yuan per share.

After this reduction, Fosun Pharma still holds 19,319,559 shares of the company, accounting for 8.30% of the total share capital. The announcement emphasizes that this reduction does not violate relevant laws and regulations and will not affect the company’s control or operations.

According to Tianyancha, Shanhe Pharmaceutical Excipients was established on April 27, 2001, with a registered capital of 234.437671 million RMB. The legal representative is Song Daocai, and the registered address is in the Economic and Technological Development Zone of Huainan City, Anhui Province. Its main business is the research, production, and sales of pharmaceutical excipients.

Currently, the company’s chairman is Wu Changhong, the secretary of the board is Liu Qi, with 1,065 employees, and the actual controller is Wu Changhong.

The company has stakes in two subsidiaries, including Hefei Shanhe Pharmaceutical Technology Co., Ltd. and Qufu Tianli Pharmaceutical Excipients Co., Ltd.

In terms of performance, the company’s operating income for 2022, 2023, and 2024 was 705 million yuan, 839 million yuan, and 883 million yuan, respectively, with year-on-year growth rates of 14.24%, 19.12%, and 5.16%. The net profit attributable to shareholders was 131 million yuan, 162 million yuan, and 119 million yuan, with year-on-year growth rates of 46.45%, 23.58%, and -26.07%. During the same period, the company’s asset-liability ratios were 33.20%, 39.38%, and 37.47%.

Regarding risks, Tianyancha data shows the company has 36 internal Tianyan risks, 11 surrounding risks, 10 historical risks, and 82 early warning risks.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes